Medtronic has introduced Tri-Ad Semi-Flexible Tricuspid Annuloplasty Ring for the treatment of tricuspid valve disease.

The Tri-Ad Semi-Flexible Tricuspid Annuloplasty Ring, acquired when Medtronic purchased ATS Medical, is an implantable annular ring that is part flexible and part semi-rigid.

The ring is designed to correct the dilated and leaking portion of the valve, thereby preserving the natural motion of the heart as it beats.

The Tri-Ad ring had received CE mark and US Food and Drug Administration (FDA) clearance in July 2010, expanding Medtronic’s surgical heart valve repair product portfolio.

The Mount Sinai Medical Center Department of Cardiothoracic Surgery chairman and Tri-Ad ring lead developer David Adams said that their understanding of the complex 3-dimensional nature of the tricuspid valve has progressed over the past several years due to advances in imaging.

“We have translated this knowledge into a new concept that combines the characteristics of the currently available tricuspid rings, which up until now have been completely rigid or completely flexible,” Adams said.

“The Tri-Ad ring has a rigid component to correct the main lesion seen in tricuspid regurgitation, in combination with completely flexible sections to protect delicate tissue.”

Medtronic Structural Heart business Surgical Based Therapies vice president Robert Perry said that the company now has the most complete heart tricuspid valve repair product portfolio for cardiac surgeons, which was made possible in part by the acquisition of ATS Medical.